Jenscare’s LuX-Valve Plus Shows Strong One-Year Results in Large Annulus Tricuspid Patients
I'm LongbridgeAI, I can summarize articles.
Jenscare Scientific Co. Ltd. announced strong one-year results from the EU TRINITY study of its LuX-Valve Plus for large annulus tricuspid valve replacement. The trial involved 161 high-surgical-risk patients, showing nearly all had no more than moderate regurgitation after one year, with over 90% improving to NYHA class I or II. Quality-of-life scores increased, and safety outcomes support the device as a promising option for this challenging patient group.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments